Immetas Overview
- Year Founded
-
2018
- Status
-
Private
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$11M
- Investors
-
1
Immetas General Information
Description
Developer of novel therapeutics designed to modulate the innate immune system to treat age-related cancer and inflammatory diseases. The company's approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases and is anchored in clinical evidence to mitigate development risk, enabling healthcare professionals to treat age-related cancer and osteoarthritis.
Contact Information
Website
www.immetas.comCorporate Office
- 120 Eagle Rock Avenue
- Suite 141
- East Hanover, NJ 07936
- United States
Corporate Office
- 120 Eagle Rock Avenue
- Suite 141
- East Hanover, NJ 07936
- United States
Immetas Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 23-Sep-2020 | $11M | Completed | Generating Revenue |
Immetas Comparisons
Industry
Financing
Details
Immetas Competitors (3)
One of Immetas’s 3 competitors is ImmunOs Therapeutics, a Venture Capital-Backed company based in Schlieren, Switzerland.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ImmunOs Therapeutics | Venture Capital-Backed | Schlieren, Switzerland | ||||
| Palleon Pharmaceuticals | Venture Capital-Backed | Waltham, MA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA |
Immetas Patents
Immetas Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022072697-A2 | Bispecific binding molecules 2 | Inactive | 30-Sep-2020 | ||
| WO-2022072697-A3 | Bispecific binding molecules 2 | Inactive | 30-Sep-2020 | ||
| AU-2020252191-A1 | Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein | Inactive | 01-Apr-2019 | ||
| CA-3135838-A1 | Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein | Pending | 01-Apr-2019 | ||
| EP-3947449-A1 | Bispecific binding molecules that target the tumor microenvironment and an immune checkpoint protein | Inactive | 01-Apr-2019 | C07K16/2818 |
Immetas Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Morningside Group | Venture Capital | Minority |
Immetas FAQs
-
When was Immetas founded?
Immetas was founded in 2018.
-
Where is Immetas headquartered?
Immetas is headquartered in East Hanover, NJ.
-
What industry is Immetas in?
Immetas’s primary industry is Drug Discovery.
-
Is Immetas a private or public company?
Immetas is a Private company.
-
What is Immetas’s current revenue?
The current revenue for Immetas is .
-
How much funding has Immetas raised over time?
Immetas has raised $11M.
-
Who are Immetas’s investors?
Morningside Group has invested in Immetas.
-
Who are Immetas’s competitors?
ImmunOs Therapeutics, Palleon Pharmaceuticals, and Intellia Therapeutics are competitors of Immetas.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process